Drug Pricing
Business & Economics
Well-Meaning Drug Discount Program Encourages Hospitals to Profit Rather than Effectively Serve Poor
A new study released today by the Pacific Research Institute finds that a program to give discounted prescription drugs to poor Americans is riddled with abuse, has created a perverse incentive for providers to profit instead of effectively serve the poor, and is hurting overall health care quality. Click here ...
Blog
Why Did the Government Swallow the 340B Fly?
Much like the old lady who swallowed a fly, the federal government has swallowed a fly over a well-meaning program designed to help the poor afford prescription drugs called 340B. Instead of ensuring the poor have low-cost drugs, 340B has created an incentive for hospitals to profit. Click here to ...
Commentary
Congress Must Reform The Broken 340B Program
The Trump administration recently announced a $1.6 billion cut to the badly abused “340B” program, which forces pharmaceutical companies to sell medicines to hospitals that treat significant numbers of poor patients at steep discounts. A bipartisan group of senators — including supposed fiscal hawks like Sens. John Thune, R-S.D., and ...
Commentary
Keep Big Government Out of Medicare Drug Pricing Negotiations
Tomorrow, the Senate Health, Education, Labor & Pensions Committee (HELP) will discuss a proposed alteration to Medicare. The proposal comes from a report released in late November by the National Academies of Sciences, Engineering, and Medicine. NASEM urges Congress to allow federal bureaucrats to negotiate Medicare drug prices directly with pharmaceutical companies. Currently, private insurance ...
Blog
There’s Plenty To Like About Trump’s HHS Pick, Alex Azar
President Trump’s nomination of Alex Azar for secretary of Health and Human Services is encouraging news for free-market health reformers. Azar possesses precisely the combination of legal acumen, bureaucratic savvy, management experience dealing with a large workforce, and private-sector experience required to eliminate those parts of Obamacare that can be accomplished through ...
Blog
PRI-Manhattan Institute Forum Addresses California’s Drug Pricing Challenge
Earlier this week, PRI joined with the Manhattan Institute to host a well-attended Sacramento panel discussion on California’s drug pricing challenge. Many thanks to my friend and former longtime Capitol reporter Marcey Brightwell, who did an outstanding job moderating the event. Drug pricing emerged as one of the hottest issues ...
California
California’s Drug Pricing Challenge
Watch a Sacramento panel discussion on California’s drug pricing challenge, co-hosted by PRI and the Manhattan Institute. Moderated by former longtime Capitol journalist Marcey Brightwell, panelists include Dr. Tom Coburn of the Manhattan Institute (and former U.S. Senator from Oklahoma), PRI’s Sally Pipes, and Brett Johnson of the California Life ...
California
Unmistakable Signs That California Lawmakers Have (Yet Again) Gone Too Far
A Mercury News headline earlier this year declared that “Amid ‘Resistance,’ activists try to push California Democratic Party to the left.” But looking back now that the bill signing period is complete, it’s clear that Sacramento Democrats don’t need to be pushed left. They’re headed that way just fine on ...
Blog
The Price Control Hammer Will Break the Health Care System
From California to Washington D.C. legislators continue to confirm Abraham Kaplan’s famous insight that if you, “give a small boy a hammer, he will find that everything he encounters needs pounding.” In the case of our legislators, that hammer is price controls; and, what needs pounding is the price of ...
Business & Economics
Price Controls Will Reduce Innovation and Health Outcomes
Abraham Kaplan famously noted that if you, “give a small boy a hammer, he will find that everything he encounters needs pounding.” Put differently, solving problems requires the right tool, not the convenient tool. Congress should remember this wisdom in its upcoming deliberations regarding the cost of prescription drugs. The ...
Well-Meaning Drug Discount Program Encourages Hospitals to Profit Rather than Effectively Serve Poor
A new study released today by the Pacific Research Institute finds that a program to give discounted prescription drugs to poor Americans is riddled with abuse, has created a perverse incentive for providers to profit instead of effectively serve the poor, and is hurting overall health care quality. Click here ...
Why Did the Government Swallow the 340B Fly?
Much like the old lady who swallowed a fly, the federal government has swallowed a fly over a well-meaning program designed to help the poor afford prescription drugs called 340B. Instead of ensuring the poor have low-cost drugs, 340B has created an incentive for hospitals to profit. Click here to ...
Congress Must Reform The Broken 340B Program
The Trump administration recently announced a $1.6 billion cut to the badly abused “340B” program, which forces pharmaceutical companies to sell medicines to hospitals that treat significant numbers of poor patients at steep discounts. A bipartisan group of senators — including supposed fiscal hawks like Sens. John Thune, R-S.D., and ...
Keep Big Government Out of Medicare Drug Pricing Negotiations
Tomorrow, the Senate Health, Education, Labor & Pensions Committee (HELP) will discuss a proposed alteration to Medicare. The proposal comes from a report released in late November by the National Academies of Sciences, Engineering, and Medicine. NASEM urges Congress to allow federal bureaucrats to negotiate Medicare drug prices directly with pharmaceutical companies. Currently, private insurance ...
There’s Plenty To Like About Trump’s HHS Pick, Alex Azar
President Trump’s nomination of Alex Azar for secretary of Health and Human Services is encouraging news for free-market health reformers. Azar possesses precisely the combination of legal acumen, bureaucratic savvy, management experience dealing with a large workforce, and private-sector experience required to eliminate those parts of Obamacare that can be accomplished through ...
PRI-Manhattan Institute Forum Addresses California’s Drug Pricing Challenge
Earlier this week, PRI joined with the Manhattan Institute to host a well-attended Sacramento panel discussion on California’s drug pricing challenge. Many thanks to my friend and former longtime Capitol reporter Marcey Brightwell, who did an outstanding job moderating the event. Drug pricing emerged as one of the hottest issues ...
California’s Drug Pricing Challenge
Watch a Sacramento panel discussion on California’s drug pricing challenge, co-hosted by PRI and the Manhattan Institute. Moderated by former longtime Capitol journalist Marcey Brightwell, panelists include Dr. Tom Coburn of the Manhattan Institute (and former U.S. Senator from Oklahoma), PRI’s Sally Pipes, and Brett Johnson of the California Life ...
Unmistakable Signs That California Lawmakers Have (Yet Again) Gone Too Far
A Mercury News headline earlier this year declared that “Amid ‘Resistance,’ activists try to push California Democratic Party to the left.” But looking back now that the bill signing period is complete, it’s clear that Sacramento Democrats don’t need to be pushed left. They’re headed that way just fine on ...
The Price Control Hammer Will Break the Health Care System
From California to Washington D.C. legislators continue to confirm Abraham Kaplan’s famous insight that if you, “give a small boy a hammer, he will find that everything he encounters needs pounding.” In the case of our legislators, that hammer is price controls; and, what needs pounding is the price of ...
Price Controls Will Reduce Innovation and Health Outcomes
Abraham Kaplan famously noted that if you, “give a small boy a hammer, he will find that everything he encounters needs pounding.” Put differently, solving problems requires the right tool, not the convenient tool. Congress should remember this wisdom in its upcoming deliberations regarding the cost of prescription drugs. The ...
